Convection-enhanced delivery of liposomal doxorubicin in intracranial brain tumor xenografts

[1]  M. Berger,et al.  Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. , 2006, Cancer research.

[2]  Ryuta Saito,et al.  Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain , 2005, Experimental Neurology.

[3]  S. Strychor,et al.  Phase I and pharmacokinetic (PK) study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors , 2005 .

[4]  Theresa M Allen,et al.  Advantages of liposomal delivery systems for anthracyclines. , 2004, Seminars in oncology.

[5]  M. Berger,et al.  Extensive Distribution of Liposomes in Rodent Brains and Brain Tumors Following Convection-Enhanced Delivery , 2004, Journal of Neuro-Oncology.

[6]  U. Matulonis,et al.  A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. , 2004, Gynecologic oncology.

[7]  M. Berger,et al.  Distribution of Liposomes into Brain and Rat Brain Tumor Models by Convection-Enhanced Delivery Monitored with Magnetic Resonance Imaging , 2004, Cancer Research.

[8]  U. Bogdahn,et al.  Pegylated liposomal doxorubicin‐efficacy in patients with recurrent high‐grade glioma , 2004, Cancer.

[9]  Raphael Pfeffer,et al.  Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. , 2004, Journal of neurosurgery.

[10]  A. Vortmeyer,et al.  Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. , 2003, Journal of neurosurgery.

[11]  R. Zhou,et al.  Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. , 2002, Cancer research.

[12]  U. Bogdahn,et al.  Long‐term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin , 2001, Cancer.

[13]  Heidi Phillips,et al.  Heparin Coinfusion during Convection-Enhanced Delivery (CED) Increases the Distribution of the Glial-Derived Neurotrophic Factor (GDNF) Ligand Family in Rat Striatum and Enhances the Pharmacological Activity of Neurturin , 2001, Experimental Neurology.

[14]  R L Fine,et al.  Tissue Distribution and Antitumor Activity of Topotecan Delivered by Intracerebral Clysis in a Rat Glioma Model , 2000, Neurosurgery.

[15]  J. Bruce,et al.  Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. , 2000 .

[16]  N. Kelekis,et al.  High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours , 2000, British Journal of Cancer.

[17]  William Jagust,et al.  Convection-Enhanced Delivery of AAV Vector in Parkinsonian Monkeys; In Vivo Detection of Gene Expression and Restoration of Dopaminergic Function Using Pro-drug Approach , 2000, Experimental Neurology.

[18]  J P Johnson,et al.  Intracerebral clysis in a rat glioma model. , 2000, Neurosurgery.

[19]  D. Papahadjopoulos,et al.  Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.

[20]  K. Gelmon,et al.  Phase I study of liposomal vincristine. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. Desoize,et al.  Cell culture as spheroids: an approach to multicellular resistance. , 1998, Anticancer research.

[22]  P. Kelly.  Survival and Functional Status after Resection of Recurrent Glioblastoma Multiforme , 1998 .

[23]  I. Roninson,et al.  Drug resistance conferred by MDR1 expression in spheroids formed by glioblastoma cell lines. , 1997, Anticancer research.

[24]  R. Straubinger,et al.  Liposome-Mediated Therapy of Intracranial Brain Tumors in a Rat Model , 1997, Pharmaceutical Research.

[25]  P F Morrison,et al.  Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. Alberts,et al.  Role of pegylated liposomal doxorubicin in ovarian cancer. , 2005, Gynecologic oncology.

[27]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[28]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[29]  D. Groothuis,et al.  The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. , 2000, Neuro-oncology.

[30]  M. Zucchetti,et al.  Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin , 1999, Cancer Chemotherapy and Pharmacology.